TY - JOUR
T1 - Pparα modulation-based therapy in central nervous system diseases
AU - Lee, Deokho
AU - Tomita, Yohei
AU - Allen, William
AU - Tsubota, Kazuo
AU - Negishi, Kazuno
AU - Kurihara, Toshihide
N1 - Funding Information:
(Figure 2), we urge further research to obtain more solid evidence on PPARα modulation Ftherapyunding:inThCNSis wodiseases.rk is supported by Grants-in-Aid for Scientific Research (KAKENHI, number 15K10881, and 18K09424) from the Ministry of Education, Culture, Sports, Science and Technology Author Contributions: T.K. and Y.T. provided technical and funding assistance. D.L. designed the study, analyzed the results, and wrote the manuscript. T.K., Y.T., K.T., W.A., and K.N. reviewed and edited the manuscript. Y.T. and T.K. supervised the study. All authors have read and agreed to the Informed Consent Statement: Not applicable.
Funding Information:
This work is supported by Grants-in-Aid for Scientific Research (KAKENHI, number 15K10881, and 18K09424) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to TK, and Alcon Research Institute and Bert M. Glaser, MD Award to YT.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors and modulators of cellular metabolism. In this regard, PPARs have recently been suggested as promising therapeutic targets for suppressing the development of CNS diseases and their progressions. While the therapeutic role of PPARγ modulation in CNS diseases has been well reviewed, the role of PPARα modulation in these diseases has not been comprehensively summarized. The current review focuses on the therapeutic roles of PPARα modulation in CNS diseases, including those affecting the brain, spinal cord, and eye, with recent advances. Our review will enable more comprehensive therapeutic approaches to modulate PPARα for the prevention of and protection from various CNS diseases.
AB - The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors and modulators of cellular metabolism. In this regard, PPARs have recently been suggested as promising therapeutic targets for suppressing the development of CNS diseases and their progressions. While the therapeutic role of PPARγ modulation in CNS diseases has been well reviewed, the role of PPARα modulation in these diseases has not been comprehensively summarized. The current review focuses on the therapeutic roles of PPARα modulation in CNS diseases, including those affecting the brain, spinal cord, and eye, with recent advances. Our review will enable more comprehensive therapeutic approaches to modulate PPARα for the prevention of and protection from various CNS diseases.
KW - Central nervous system
KW - Eye
KW - Peroxisome proliferator-activated receptors
UR - http://www.scopus.com/inward/record.url?scp=85119008424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119008424&partnerID=8YFLogxK
U2 - 10.3390/life11111168
DO - 10.3390/life11111168
M3 - Review article
AN - SCOPUS:85119008424
SN - 0024-3019
VL - 11
JO - Life
JF - Life
IS - 11
M1 - 1168
ER -